Referencias bibliográficas

1. Nourbakhsh BB, Mowry EM. Multiple Sclerosis Risk Factors and Pathogenesis. Contin (Minneap Minn) Neurol. 2019;25(3):596-610. [Pubmed]
2. Tsunoda I, Fujinami RS. Inside-Out versus Outside-In models for virus induced demyelination: axonal damage triggering demyelination. Springer Semin Immunopathol. 2002;24(2):105-25. [Pubmed]
3. Tsunoda I, Tanaka T, Terry EJ, Fujinami RS. Contrasting Roles for Axonal Degeneration in an Autoimmune versus Viral Model of Multiple Sclerosis When Can Axonal Injury Be Beneficial ? Am J Pathol. 2007;170(1):214-26. [Pubmed]
4. Villar LM, Masjuán J, González-Porqué P, Plaza J, Sádaba MC, Roldán E, et al. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology. 2002;59(4):555-9. Disponible en: [Enlace]
5. Hohlfeld R, Dornmair K, Meinl E, Wekerle H. The search for the target antigens of multiple sclerosis, part 1: Autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets. Lancet Neurol. 2016;15(2):198-209. [Pubmed]
6. Fierz W. Pathogenesis of Multiple Sclerosis : How Much Space is Left for Autoimmunity? J Mult Scler. 2017;(4):2. Disponible en: [Enlace]
7. Willis SN, Stathopoulos P, Chastre A, Compton SD, Connor KCO. Investigating the Antigen Specificity of Multiple Sclerosis Central Nervous System-Derived Immunoglobulins. Front Immunol. 2015;6:1-9. [Pubmed]
8. Brandle SM, Obermeier B, Senel M, Bruder J, Mentele R, Khademi M, et al. Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins. Proc Natl Acad Sci U S A. 2016;113(28):7864-69. [Pubmed]
9. Frisullo G, Nociti V, Iorio R, Patanella AK, Marti A, Caggiula M, et al. IL17 and IFNγ production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis. Cytokine. 2008;44(1):22-5. [Pubmed]
10. Rolla S, Bardina V, De Mercanti S, Quaglino P, De Palma R, Gned D, et al. Th22 cells are expanded in multiple sclerosis and are resistant to IFN-β. J Leukoc Biol. 2014;96(6):1155-64. [Pubmed]
11. Barr TA, Shen P, Brown S, Lampropoulou V, Roch T, Lawrie S, et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med. 2012;209(5):1001-10. [Pubmed]
12. Bar-Or A, Fawaz L, Fan B, Darlington PJ, Rieger A, Ghorayeb C, et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol. 2010;67(4):452-61. [Pubmed]
13. Kinnunen T, Chamberlain N, Morbach H, Cantaert T, Lynch M, Preston-Hurlburt P, et al. Specific peripheral B cell tolerance defects in patients with multiple sclerosis. J Clin Invest. 2013;123(6):2-6. [Pubmed]
14. Sørensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest. 1999;103(6):807-15. [Pubmed]
15. Zozulya AL, Wiendl H. The role of regulatory T cells in multiple sclerosis. Nat Clin Pract Neurol. 2008;4(7):384-98. [Pubmed]
16. Baranzini SE, Oksenberg JR. The Genetics of Multiple Sclerosis: From 0 to 200 in 50 Years. Trends Genet. 2017;33(12):960-70. [Pubmed]
17. Parnell GP, Booth DR. The Multiple Sclerosis (MS) Genetic Risk Factors Indicate both Acquired and Innate Immune Cell Subsets Contribute to MS Pathogenesis and Identify Novel Therapeutic Opportunities. Front Immunol. 2017;8:425. [Pubmed]
18. Dobson R, Giovannoni G. Autoimmune disease in people with multiple sclerosis and their relatives: a systematic review and meta-analysis. J Neurol. 2013;260(5):1272-85. [Pubmed]
19. Tuller T, Atar S, Ruppin E, Gurevich M, Achiron A. Common and specific signatures of gene expression and protein-protein interactions in autoimmune diseases. Genes Immun. 2013;14(2):67-82. [Pubmed]
20. University of California, San Francisco MS-EPIC Team, Cree BAC, Hollenbach JA, Bove R, Kirkish G, Sacco S, Caverzasi E, Bischof A, et al. Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol. 2019 May;85(5):653-66. [Pubmed]
21. Kappos L, Wolinsky JS, Giovannoni G, Arnold DL, Wang Q, Bernasconi C, et al. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. JAMA Neurol. 2020 Sep 1;77(9):1132-40. [Pubmed]
22. Locatelli G, Wörtge S, Buch T, Ingold B, Frommer F, Sobottka B, et al. Primary oligodendrocyte death does not elicit anti-CNS immunity. Nat Publ Gr. 2012;15(4):543-50. [Pubmed]
23. Traka M, Podojil JR, Mccarthy DP, Miller SD, Popko B. Oligodendrocyte death results in immune-mediated CNS demyelination. Nat Neurosci. 2015;19(1):65-74. [Pubmed]
24. Caprariello AV, Rogers JA, Morgan ML, Hoghooghi V, Plemel JR, Koebel A. Biochemically altered myelin triggers autoimmune demyelination. Proc Natl Acad Sci U S A. 2018 May 22;115(21):5528-33. [Pubmed]
25. Stys PK, Zamponi GW, Minnen J Van, Geurts JJG. Will the real multiple sclerosis please stand up? Nat Rev Neurol. 2012;13:507-14. [Pubmed]
26. Tsunoda I, Kuang L, Libbey JE, Fujinami RS. Axonal Injury Heralds Virus-Induced Demyelination. Am J Pathol. 2003;162(4):1259-69. [Pubmed]
27. Tsunoda I, Tanaka T, Saijoh Y, Fujinami RS. Targeting Inflammatory demyelinating lesions to sites of Wallerian degeneration. Am J Pathol. 2007;171(5):1563-75. [Pubmed]
28. Santis S De, Granberg T, Ouellette R, Treaba CA, Herranz E, Fan Q, et al. Evidence of early microstructural white matter abnormalities in multiple sclerosis from multi-shell diffusion MRI. Neuroimage Clin. 2019;22:101699. [Pubmed]
29. De Santis S, Granberg T, Ouellette R, Treaba CA, Qiuyun Fan, Herranz E, et al. Early axonal damage in normal appearing white matter in multiple sclerosis: Novel insights from multi-shell diffusion MRI. Conf Proc Annu Int Conf IEEE Eng Med Biol Soc IEEE Eng Med Biol Soc. July 2017:3024-27. [Pubmed]
30. Rodríguez M, Scheithauer B. Ultrastructure of multiple sclerosis. Ultrastruct Pathol. 1994;18(1-2):3-13. [Pubmed]
31. Laurence M, Benito-león J. Epstein-Barr Virus and Multiple Sclerosis: Updating Pender’s Hypothesis. Mult Scler Relat Disord. 2017;16:8-14. [Pubmed]
32. Castellazzi M, Tamborino C, Cani A, Negri E, Baldi E, Seraceni S, et al. Epstein-Barr virus-specific antibody response in cerebrospinal fluid and serum of patients with multiple sclerosis. Mult Scler. 2010;16(7):883-7. [Pubmed]
33. Van Nierop GP, Mautner J, Mitterreiter JG, Hintzen RQ, Verjans GM. Intrathecal CD8 T-cells of multiple sclerosis patients recognize lytic Epstein-Barr virus proteins. Mult Scler J. 2016;22(3):279-91. [Pubmed]
34. Pender MP. The essential role of Epstein-Barr virus in the pathogenesis of multiple sclerosis. Neuroscientist. 2011;17(4):351-67. [Pubmed]
35. Hassani A, Corboy JR, Al-Salam S, Khan G. Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells. PLoS One. 2018;13(2):1-19. [Pubmed]
36. Rose NR. Molecular mimicry and clonal deletion: A fresh look. J Theor Biol. 2015;375:71-6. [Pubmed]
37. Geginat J, Paroni M, Pagani M, Galimberti D, De Francesco R, Scarpini E, Abrignani S. The Enigmatic Role of Viruses in Multiple Sclerosis : Molecular Mimicry or Disturbed Immune Surveillance? Trends Immunol. 2017;38(7):498-512. [Pubmed]
38. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell. 1995;80(5):695-705. [Pubmed]
39. Lünemann JD, Jelčić I, Roberts S, Lutterotti A, Tackenberg B, Martin R, Münz C. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-γ and IL-2. J Exp Med. 2008;205(8):1763-73. [Pubmed]
40. Broccolo F, Fusetti L, Ceccherini-nelli L. Possible Role of Human Herpesvirus 6 as a Trigger of Autoimmune Disease. Sci world J. 2013:867389. [Pubmed]
41. Harkiolaki M, Holmes SL, Svendsen P, Gregersen JW, Jensen LT, McMahon R, et al. T Cell-Mediated Autoimmune Disease Due to Low-Affinity Crossreactivity to Common Microbial Peptides. Immunity. 2009;30(3):348-57. [Pubmed]
42. Bar-Or A, Pender MP, Khanna R, Steinman L, Hartung HP, Maniar T, Croze E, Aftab BT, Giovannoni G, Joshi MA. Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies. Trends Mol Med. 2020 Mar;26(3):296-310. [Pubmed]
43. Guan Y, Jakimovski D, Ramanathan M, Weinstock-Guttman B, Zivadinov R. The role of Epstein-Barr virus in multiple sclerosis : from molecular pathophysiology to in vivo imaging. Neural Regen Res. 2018;14(3):373-86. [Pubmed]
44. Hottenrott T, Dersch R, Berger B, Rauer S, Eckenweiler M, Huzly D, Stich O. The intrathecal, polyspecific antiviral immune response in neurosarcoidosis, acute disseminated encephalomyelitis and autoimmune encephalitis compared to multiple sclerosis in a tertiary hospital cohort. Fluids Barriers CNS. 2015;12(1):1-5. [Pubmed]
45. Ruprecht K, Wildemann B, Jarius S, Ruprecht K. Low intrathecal antibody production despite high seroprevalence of Epstein – Barr virus in multiple sclerosis : a review of the literature. J Neurol. 2018;265(2):239-52. [Pubmed]
46. Yadav SK, Mindur JE, Ito K, Dhib-Jalbut S. Advances in the immunopathogenesis of multiple sclerosis. Curr Opin Neurol. 2015;28(3):206-19. [Pubmed]
47. International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2, Sawcer S, Hellenthal G, Pirinen M, Spencer CC, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476:214-9. [Pubmed]
48. Pytel V, Matias-Guiu JA, Torre-Fuentes L, Montero-Escribano P, Maietta P, Botet J, et al. Exonic variants of genes related to the vitamin D signaling pathway in the families of familial multiple sclerosis using whole-exome next generation sequencing. Brain Behav. 2019;9(4):e01272. [Pubmed]
49. Gao Z, Nissen JC, Ji K, Tsirka SE. The experimental autoimmune encephalomyelitis disease course is modulated by nicotine and other cigarette smoke components. PLoS One. 2014;9(9):e107979. [Pubmed]
50. Robinson WH, Utz PJ, Steinman L. Genomic and proteomic analysis of multiple sclerosis: Opinion. Curr Opin Immunol. 2003;15(6):660-7. Disponible en: [Enlace]
51. Messina S, Vargas-Lowy D, Musallam A, Healy BC, Kivisakk P, Gandhi R, et al. Increased leptin and A-FABP levels in relapsing and progressive forms of MS. BMC Neurol. 2013;13(1):172. [Pubmed]
52. Farrokhi M, Dabirzadeh M, Fadaee E, Beni AA, Saadatpour Z, Rezaei A, Heidari Z. Polymorphism in Leptin and Leptin Receptor Genes May Modify Leptin Levels and Represent Risk Factors for Multiple Sclerosis. Immunol Invest. 2016;45(4):328-35. [Pubmed]
53. Frisullo G, Angelucci F, Mirabella M, Caggiula M, Patanella K, Nociti V, et al. Leptin enhances the release of cytokines by peripheral blood mononuclear cells from relapsing multiple sclerosis patients. J Clin Immunol. 2004;24(3):287-93. Disponible en: [Enlace]
54. Matarese G, Carrieri PB, La Cava A, Perna F, Sanna V, De Rosa V, et al. Leptin increase in multiple sclerosis associates with reduced number of CD4+CD25+ regulatory T cells. Proc Natl Acad Sci U S A. 2005;102(14):5150-5. [Pubmed]
55. Lanzillo R, Carbone F, Quarantelli M, Bruzzese D, Carotenuto A, De Rosa V, et al. Immunometabolic profiling of patients with multiple sclerosis identifies new biomarkers to predict disease activity during treatment with interferon beta-1a. Clin Immunol. 2017;183:249-53. [Pubmed]